Topics Covered: Biology, Prevention, Testing and Screening, Operable Colorectal Cancer, Management of Hepatic Metastases, Innovative Strategies for Metastatic Colorectal Cancer, Chemotherapy
Conference Objectives: A faculty of expert specialists will present their perspectives on the current management and areas of research that seem likely to make an impact on management of this disease in the future.
Who Should Attend: practicing clinicians, gastro-enterologists, colorectal surgeons, medical oncologists, and radiation oncologists who wish to review and update their knowledge and management of colorectal cancer.
Thursday September 19, 2002
8:00 am Welcome and Introduction: Richard M. Goldberg, Mayo Clinic, Rochester, MN
Session I: Biology
8:05am The role of the APC gene and its mutations in the genesis of colon polyps and colon cancer
8:30 am Microsatellite instability and mismatch repair genes in colorectal cancer
8:55 am Clinical correlates of the various genetic alterations of colorectal cancer in terms of prognosis, and selection of therapies
9:20 am Intracellular signaling pathways in colorectal cancer
9:45 am Q&A
Session II: Prevention, testing, and screening
10:20 Genetic testing and counseling for colorectal cancer
10:45 NSAIDS, Cox-2 inhibitors, and other measures for colon cancer prevention: rationale and clinical results
11:10 Cost effective screening for colorectal cancer
11:35 Fecal DNA markers as screening tools
Session III: Operable colorectal cancer
2:00 pm Total mesorectal excision
2:25 pm Operable colorectal cancers: local excision with or without adjuvant therapy?
2:50 pm Laparoscopic surgery for colorectal cancer
3:15 pm Preoperative vs postoperative adjuvant treatment for rectal cancer
3:40 pm Postoperative surveillance for recurrences, and Nicholas metachronous new primaries?
4:05 pm Q&A
4:15 pm Break
Session IV: Management of hepatic metastases
4:35 pm Preoperative or postoperative chemotherapy for hepatic (and lung?) metastases?
5:00 New ablation techniques
5:25 Combined intraarterial and systemic chemotherapy
Friday September 20, 2002
Session V: Innovative strategies for metastatic colorectal cancer
8:00 am Anti-EGFR and anti-VEGF antibodies in colorectal cancer
8:25 Inhibitors of intracellular signaling in colorectal cancer
8:50 Gene therapy for colorectal cancer
9:15 Replication selective adenoviruses in colorectal cancer treatment
Session V: Chemotherapy
10:10 Predictors of response to 5FU based therapy: should we measure TS and other enzymes?
10:35 Pharmacogenomics of colorectal cancer
11:00 Optimal first line therapy
2:00 Sequential vs combination chemotherapy
2:25 Oral colorectal cancer treatment
2:50 Second line or salvage therapy.
3:15 Colorectal cancer treatment in Europe and the U.S
Registration Information: Four EASY ways to register:
FAX US...(770) 751 7334
PHONE US...(770) 751 7332
WRITE US... Imedex 70 Technology Drive Alpharetta GA 30005-3969 USA
Jul 7, 2010 - Colorectal cancer screening rates have increased in the United States since 2002 and mammography rates have plateaued, while millions of people have not undergone recommended colorectal cancer screening, and millions of women have not had a recent mammogram, according to research published July 6 in an early issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.